溴隐亭治疗女性不明原因的生育力低下
Bromocriptine for unexplained subfertility in women.
作者信息
Hughes E, Collins J, Vandekerckhove P
机构信息
Rm HSC-4F7, Department of Obstetrics and Gynaecology, McMaster University, 1200 Main St West, Hamilton, Ontario, Canada, L8N 3Z5.
出版信息
Cochrane Database Syst Rev. 2000(2):CD000044. doi: 10.1002/14651858.CD000044.
BACKGROUND
Bromocriptine improves hyperprolactinemic amenorrhea and so could also be helpful in the treatment of unexplained subfertility in women.
OBJECTIVES
To assess the effects of bromocriptine in women with unexplained subfertility.
SEARCH STRATEGY
The Cochrane Subfertility Review Group specialised register of controlled trials was searched.
SELECTION CRITERIA
Randomised trials comparing bromocriptine with placebo or no treatment in women with unexplained subfertility.
DATA COLLECTION AND ANALYSIS
Two reviewers applied the eligibility criteria and assessed trial quality independently.
MAIN RESULTS
Three trials involving of 127 women were included. All trials were double-blind comparisons with placebo, and one was of crossover design. Conception rates with bromocriptine treatment did not improve compared with placebo (odds ratio was 1.12, 95% confidence interval 0.48 to 2.57).
REVIEWER'S CONCLUSIONS: There is not enough evidence to evaluate bromocriptine use in women with unexplained subfertility. However trials for women with unexplained subfertility who also have expressible galactorrhea may be worthwhile.
背景
溴隐亭可改善高泌乳素血症性闭经，因此可能有助于治疗女性不明原因的不孕症。
目的
评估溴隐亭对不明原因不孕症女性的疗效。
检索策略
检索了Cochrane不孕症综述小组专门的对照试验登记册。
选择标准
比较溴隐亭与安慰剂或不治疗对不明原因不孕症女性疗效的随机试验。
数据收集与分析
两名评价者应用纳入标准并独立评估试验质量。
主要结果
纳入了3项涉及127名女性的试验。所有试验均为与安慰剂的双盲比较，其中1项为交叉设计。与安慰剂相比，溴隐亭治疗的受孕率未提高（优势比为1.12，95%置信区间为0.48至2.57）。
评价者结论
没有足够的证据评估溴隐亭在不明原因不孕症女性中的应用。然而，对同时有可挤出性溢乳的不明原因不孕症女性进行试验可能是值得的。
Zotero 插件